Dianthus Therapeutics Conference Call Summary Company Overview - **Company**: Dianthus Therapeutics (NasdaqCM:DNTH) - **Date**: February 12, 2026 - **Key Executives**: Marino Garcia (CEO), Ryan Savitz (CFO) Key Industry and Company Insights 1. Transformational Year - 2025 was a pivotal year for Dianthus, marked by the first patient data in myasthenia gravis (MG), which exceeded expectations [2][60] 2. Product Pipeline - **DNTH212**: In-licensed from Leads Biolabs, a bifunctional fusion protein targeting BDCA2 to reduce type I interferon and BAFF/APRIL, showing potential as a best-in-class product [2][3] - **Clasiprubart**: An active C1s inhibitor with promising phase 2 data for MG, with two major catalysts expected in 2026 [3][4] 3. Upcoming Catalysts - **CIDP Phase 3 Study**: Interim responder analysis for the first 40 patients is anticipated in Q2 2026, accelerated from H2 2026 due to strong recruitment [4][16] - **MMN Phase 2 Results**: Expected in the second half of 2026 [4] 4. Competitive Landscape - **Riliprubart**: A competitor from Sanofi, currently in phase 3 studies for CIDP. Dianthus aims to demonstrate at least equal efficacy with a more convenient dosing regimen [10][12] - **Empaciperbart**: Another competitor in MMN, with Dianthus expecting similar efficacy but with advantages in administration and safety [31][39] 5. Efficacy Expectations - For CIDP, Dianthus aims for a responder rate of 40%-50% in the interim analysis, comparable to riliprubart's phase 2 data [12][17] - The company is focusing on a dosing regimen that is more efficient, potentially reducing the number of injections required [12][15] 6. Market Potential - The U.S. market for MG is estimated at $5 billion, with potential growth to $20-$25 billion as biologics penetrate further [60] - Dianthus anticipates capturing 5%-10% of the MG market, translating to $2-$4 billion in sales [60][62] 7. Financial Health - Dianthus ended the year with $514 million in cash, sufficient to fund operations through 2028 and support upcoming milestones [64] 8. Safety and Regulatory Considerations - Concerns about drug-induced lupus (DIL) were addressed, emphasizing the reliability of data from clinical trials versus anecdotal reports [54][56] - The company is confident in the safety profile of its products, with no reported cases of DIL in clinical programs [56] 9. Commercial Strategy - Dianthus plans to leverage the convenience of its auto-injector and the absence of a box warning to differentiate its products in the market [41][44] 10. Recruitment and Trial Design - The company is focusing on efficient recruitment strategies and trial designs that allow for quicker results and better patient outcomes [16][20] Conclusion Dianthus Therapeutics is positioned for significant growth with a strong pipeline and strategic focus on efficacy, safety, and market penetration. The upcoming data releases and competitive advantages in product administration are critical to its success in the evolving biotech landscape.

Core Insights - Regeneron Pharmaceuticals (REGN) reported a solid performance for Q4 2025 and full-year 2025, with overall revenues increasing despite a significant decline in sales of its flagship product, Eylea [1] Eylea Performance - Eylea sales in the U.S. fell by 42% to $2.7 billion in 2025, driven by competitive pressures, market share loss to compounded bevacizumab, and patient transitions to Eylea HD [2] - Eylea remains Regeneron's largest revenue contributor, but declining sales are impacting overall revenues [3] - Eylea HD, a higher-dose formulation, saw sales increase by 36% to $1.6 billion in the U.S. in 2025, as Regeneron aims to defend its market share [5][10] Competitive Landscape - Roche's Vabysmo has intensified competition, achieving sales growth of 12% to CHF 4.1 billion in 2025 [4] - Regeneron introduced Eylea HD to improve durability and extend dosing intervals in response to competitive pressures [4] Future Projections - Eylea sales are expected to decline further in 2026, particularly in the second half of the year as multiple biosimilars enter the U.S. market [5][10] - Eylea HD is gaining traction due to steady label expansions, with recent FDA approvals enhancing its market position [6][7] Other Revenue Streams - Regeneron's revenue is bolstered by its share of profits from global Dupixent sales, which continue to grow due to strong demand across various indications [8] - Libtayo, Regeneron's PD-1 inhibitor, generated $1.4 billion in sales in 2025, reflecting a 19% year-over-year increase [11] Oncology Developments - The oncology portfolio received a boost with the FDA's accelerated approval of linvoseltamab-gcpt for relapsed or refractory multiple myeloma [12] - The European Commission approved Ordspono for relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma, further strengthening Regeneron's oncology franchise [13] Pipeline and Future Approvals - Regeneron has a robust pipeline, with additional drug approvals expected to support revenue growth [13] - The company submitted a biologics license application for DB-OTO, a gene therapy for profound genetic hearing loss, with a decision expected in H1 2026 [14] - Regeneron is also pursuing approval for garetosmab for fibrodysplasia ossificans progressiva and expanding its obesity-focused pipeline [15]

2026.02. 12 本文字数：2499，阅读时长大约4分钟 作者 | 第一财经 林志吟 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获 得拟中选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、 呼吸系统、消化系统等26个治疗领域。 从这接续采购的316种药品来看，据第一财经记者统计，有原研药中标的品种共有21个，整体占比 不到一成。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的 水分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新 药，满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份 全部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资 格的企业绝大多数参与投标报价，整体中选率高达93%，每个品种平均14家企业中选。 本次接续采购，国内药品上市许可持有人（含药品注册批件持有人）、境外药品上市许可持有人及其 境内责任 ...

Core Viewpoint - Sanofi's stock experienced a significant decline following the unexpected ousting of CEO Paul Hudson by the board, who has been replaced by Belen Garijo from Merck KGaA [1] Group 1: Company Performance - Sanofi recently reported fourth-quarter earnings that exceeded Wall Street expectations, but the sales figures were lighter than anticipated [1] - The company is widely recognized for its blockbuster drug Dupixent, developed in collaboration with Regeneron Pharmaceuticals, which treats allergic conditions [1] Group 2: Leadership Changes - The abrupt removal of Paul Hudson as CEO has raised concerns among investors, leading to a drop in Sanofi's stock price [1] - Belen Garijo's appointment as the new CEO marks a significant leadership change within the company [1]

凭借品牌优势在院外市场找到新的发展空间。 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获得拟中 选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系 统、消化系统等26个治疗领域。 2018年以来，随着国家组织的药品集采启动，医药行业逐渐走向分水岭，过了专利保护期的原研药难以 在中国市场维持高利润且垄断局面，而原来以销售这类药物为生的跨国药企这几年已在密集调整业务， 重塑在华发展战略。 一些原研药虽然缺席集采，但并不意味着从市场消失，相反凭借品牌优势仍在院外市场找到新的发展空 间。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的水 分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新药， 满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份全 部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资格的 企业绝大多数参与投标报价 ...

Market Movements - US stock index futures are all up, with Dow futures rising by 0.33%, S&P 500 futures up by 0.31%, and Nasdaq futures increasing by 0.29% [1] - European indices also show positive movement, with Germany's DAX up by 1.22%, UK's FTSE 100 up by 0.11%, France's CAC40 up by 0.74%, and the Euro Stoxx 50 up by 0.59% [2] Oil Prices - WTI crude oil is down by 0.09%, priced at $64.57 per barrel, while Brent crude oil is down by 0.17%, priced at $69.28 per barrel [3] Economic and Market News - David Einhorn of Greenlight Capital predicts that the Federal Reserve will cut interest rates "far more than twice" this year, contrary to market expectations, citing political pressure and upcoming leadership changes at the Fed as catalysts for aggressive rate cuts [4] - John Cito from Apollo Asset Management warns that the software industry is entering a "violent technology cycle," with a significant reset in valuation logic as the market begins to aggressively differentiate between winners and losers [5] - The Federal Reserve is reportedly planning to revoke certain non-public corrective orders issued to banks, signaling a potential easing of regulatory burdens [6] Employment Data - The US non-farm payrolls report for January showed an increase of 130,000 jobs, significantly exceeding the market expectation of 70,000, leading to a delay in rate cut expectations from June to July [7] - Moody's Chief Economist Mark Zandi cautions against overconfidence in the employment data, suggesting that the labor market remains fragile and susceptible to shocks [7] Company-Specific News - Apple (AAPL.US) faces delays in its AI upgrade plan for Siri, with significant features potentially being rolled out in multiple phases rather than all at once [9] - Sanofi (SNY.US) announced a sudden CEO change, with Paul Hudson stepping down amid disappointing R&D results, leading to a drop in stock price by over 6% [10] - Cisco (CSCO.US) reported a 10% year-over-year revenue increase to $15.3 billion, but stock fell over 7% due to concerns over future profit margins amid rising storage chip costs [11] - Applovin (APP.US) reported a 66% revenue increase in Q4, with net profit soaring by 84%, indicating strong performance in the AI and digital advertising space [12] - McDonald's (MCD.US) achieved its fastest revenue growth in over two years, with Q4 sales reaching $7 billion, driven by value meal offerings [13] - Confluent (CFLT.US) exceeded expectations in Q4, with revenue rising by 21% to $314.8 million, marking a strong performance before its acquisition by IBM [14] - Albemarle (ALB.US) reported a Q4 revenue of $1.43 billion but faced a net loss of $455.9 million, leading to a drop in stock price by over 2% [15] - Unilever (UL.US) reported Q4 sales of €12.6 billion, slightly down year-over-year, but expects stable growth in 2026, supported by a €1.5 billion share buyback plan [16]

Market Movements - US stock index futures are all up, with Dow futures rising by 0.33%, S&P 500 futures up by 0.31%, and Nasdaq futures increasing by 0.29% [1] - European indices also show positive movement, with Germany's DAX up by 1.22%, UK's FTSE 100 up by 0.11%, France's CAC40 up by 0.74%, and the Euro Stoxx 50 up by 0.59% [2] Oil Prices - WTI crude oil is down by 0.09%, priced at $64.57 per barrel, while Brent crude oil is down by 0.17%, priced at $69.28 per barrel [3] Economic and Market News - David Einhorn of Greenlight Capital predicts that the Federal Reserve will cut interest rates "far more than two times" this year, contrary to market expectations, citing political pressure and upcoming leadership changes at the Fed as catalysts for aggressive rate cuts [4] - Apollo Global Management warns that the software industry is entering an "extremely violent technology cycle," with a significant reset in valuation logic, emphasizing the need for humility in understanding future market dynamics [5] - The Federal Reserve is signaling a reduction in regulatory burdens for banks, planning to revoke certain non-public corrective orders that were previously issued to improve operations [6] Employment Data - The US non-farm payrolls report for January shows an increase of 130,000 jobs, significantly exceeding the market expectation of 70,000, with the unemployment rate dropping to 4.3% [7] - Moody's chief economist Mark Zandi cautions against overconfidence in the employment data, suggesting that the labor market remains fragile and could easily face shocks [7] Company-Specific News - Apple faces delays in its AI upgrade for Siri, with significant features being split into multiple releases due to testing setbacks [9] - Sanofi announces a leadership change, with CEO Paul Hudson being replaced by Merck executive Paul Garibaldi, following disappointing R&D results [10] - Cisco's Q2 revenue increased by 10% to $15.3 billion, but the stock fell over 7% due to concerns about future profit margins amid rising storage chip costs [11] - Applovin reports a 66% increase in Q4 revenue to $1.66 billion, with net profit soaring by 84%, indicating strong performance in the AI and digital advertising space [12] - McDonald's sees a 9.5% increase in Q4 revenue, driven by value meal offerings, marking the fastest growth in over two years [13] - Confluent's Q4 revenue reaches $314.8 million, with a 21% year-over-year increase, as the company prepares for privatization by IBM [14] - Albemarle reports a Q4 revenue of $1.43 billion but faces a net loss of $455.9 million, leading to a shutdown of key production lines [15] - Unilever's Q4 sales exceed expectations, driven by strong performance in key markets, with a forecast for 2026 sales growth aligning with analyst expectations [16]

Group 1 - Sanofi announced the ouster of CEO Paul Hudson after a six-year tenure, during which Dupixent became one of the world's best-selling medicines [7] - Belén Garijo, the current CEO of Merck KGaA, will replace Hudson, with Olivier Charmeil serving as interim CEO after Hudson's departure [7] - Sanofi expressed confidence in Garijo's leadership, highlighting her previous successes and reputation in the industry [5] Group 2 - Initial investor reactions to the leadership change were negative, with Sanofi's shares dropping about 3% in late trading in Europe [3] - Analysts have raised concerns regarding Garijo's lack of a credible R&D track record and the implications for corporate governance and growth [6] - Despite the challenges, Sanofi believes Garijo will enhance the implementation of its strategy and improve R&D productivity and innovation capacity [7]

Core Viewpoint - Some pharmaceutical companies not included in President Trump's drug price reduction agreement are developing their own plans to avoid potential harsh tariffs and new pricing mechanisms [1][4]. Group 1: Companies Involved - As of now, 16 major pharmaceutical companies, including Pfizer and Eli Lilly, have reached agreements with the government after receiving price reduction directives [1][4]. - Many companies, approximately half of which are members of the Pharmaceutical Research and Manufacturers of America (PhRMA), have not yet been contacted by the government [1][4]. - Bayer's global pharmaceutical business head, Stefan Oelrich, expressed optimism that companies like Bayer, which did not receive directives, would have opportunities to reach similar agreements with competitors [1][4]. Group 2: Concerns of Smaller Companies - A group of mid-sized companies has formed the American Mid-Sized Biotechnology Alliance to oppose the new pricing mechanisms [2][5]. - Sanofi's CEO, Paul Hudson, noted that many companies have not reached agreements and questioned what options they have [2][5]. - Hudson also indicated that the nature of existing agreements might make it difficult for the government to offer similar options to smaller companies [2][5]. Group 3: Pricing Mechanisms and Implications - U.S. patients pay the highest prescription drug prices globally, often nearly three times higher than in other developed countries [3][6]. - Agreements signed by large pharmaceutical companies commit to lowering drug prices for Medicaid, but analysts suggest the impact may be limited since Medicaid accounts for only 10% of U.S. drug spending [3][6]. - Companies that have not reached agreements will face constraints from Medicare pilot programs, GLOBE and GUARD, which will implement most-favored-nation pricing, aligning U.S. drug prices with lower international prices [3][6]. - Concerns exist that mid-sized companies, having fewer products to negotiate, may not have low-revenue drugs to "sacrifice" in negotiations [3][6].

Sanofi replaced Hudson after a massive research spending boost failed to deliver rapid results https://t.co/vTi599fe7Q ...